BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/2/2015 12:24:00 PM | Browse: 1268 | Download: 1355
 |
Received |
|
2013-12-31 08:56 |
 |
Peer-Review Started |
|
2013-12-31 09:38 |
 |
To Make the First Decision |
|
2014-02-27 10:44 |
 |
Return for Revision |
|
2014-03-04 21:03 |
 |
Revised |
|
2014-03-26 03:59 |
 |
Second Decision |
|
2014-06-03 16:16 |
 |
Accepted by Journal Editor-in-Chief |
|
|
 |
Accepted by Executive Editor-in-Chief |
|
2014-06-03 16:30 |
 |
Articles in Press |
|
2014-06-03 16:52 |
 |
Publication Fee Transferred |
|
|
 |
Edit the Manuscript by Language Editor |
|
|
 |
Typeset the Manuscript |
|
2014-08-11 08:40 |
 |
Publish the Manuscript Online |
|
2014-08-20 20:37 |
Category |
Rheumatology |
Manuscript Type |
Topic Highlights |
Article Title |
Efficacy and safety of tofacitinib for treatment of rheumatoid arthritis
|
Manuscript Source |
Invited Manuscript |
All Author List |
Lisa M Lundquist, Sabrina W Cole and Martha L Sikes |
Funding Agency and Grant Number |
|
Corresponding Author |
Lisa M Lundquist, PharmD, BCPS, College of Health Professions, Mercer University, 3001 Mercer University Drive, Atlanta, GA 30341,
United States. lundquist_lm@mercer.edu
|
Key Words |
Tofacitinib; Rheumatoid arthritis; Janus kinase inhibitor |
Core Tip |
Tofacitinib, a Janus kinase inhibitor, is a targeted, synthetic, disease-modifying antirheumatic drug (DMARD) approved for the treatment of moderately to severely active rheumatoid arthritis in patients who have had an inadequate response to methotrexate. In numerous phase 2 and 3 trials, tofacitinib has proven to be safe and effective as monotherapy or in combination with methotrexate or other non-biologic DMARDs.
|
Publish Date |
2014-08-20 20:37 |
Citation |
Lundquist LM, Cole SW, Sikes ML. Efficacy and safety of tofacitinib for treatment of rheumatoid arthritis. World J Orthop 2014; 5(4): 504-511 |
URL |
http://www.wjgnet.com/2218-5836/full/v5/i4/504.htm |
DOI |
http://dx.doi.org/10.5312/wjo.v5.i4.504 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345